Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Anti-inflammatory Effect of CHF6523 in Healthy and COPD Subjects
NCT04032535Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CHF6523 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Treatment Emergent Adverse Events up to 4 weeks. Started Jul 2019; status: completed.
02
Drugs
CHF6523
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04032535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032535.